Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

2026-03-11 - 12:13

“Spinal muscular atrophy has benefitted from extraordinary therapeutic progress, but across the treatment landscape there remains room for improvement. There is growing scientific and clinical enthusiasm about the advances that salanersen offers,” said Thomas Crawford, M.D., co-director, Muscular Dystrophy Association Clinic at Johns Hopkins Medicine. “These additional Phase 1 data add confidence in the emerging salanersen clinical profile. We have more reason to look forward to results of the Phase 3 program." Read More